Go Pro
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
$0.00
$0.00
$0.00
▼
$0.56
$50K-9.0965,372 shs999 shs
Evogene Ltd. stock logo
EVGN
Evogene
$0.55
+1.5%		$0.53
$0.37
▼
$1.50
$4.81M1.4915,615 shs3,294 shs
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
$0.00
-12.0%		$0.00
$0.00
▼
$0.03
$137K1.88110,988 shs6,704 shs
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
$0.01
$0.01
$0.00
▼
$0.07
$66K1.445,159 shs733 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
0.00%-45.45%-73.33%+1,100.00%-99.50%
Evogene Ltd. stock logo
EVGN
Evogene
-1.18%-9.64%+4.42%-24.07%-58.55%
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
-14.00%+10.26%+7.50%-29.51%-86.13%
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
0.00%0.00%0.00%0.00%-78.80%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
$0.00
$0.00
$0.00
▼
$0.56
$50K-9.0965,372 shs999 shs
Evogene Ltd. stock logo
EVGN
Evogene
$0.55
+1.5%		$0.53
$0.37
▼
$1.50
$4.81M1.4915,615 shs3,294 shs
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
$0.00
-12.0%		$0.00
$0.00
▼
$0.03
$137K1.88110,988 shs6,704 shs
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
$0.01
$0.01
$0.00
▼
$0.07
$66K1.445,159 shs733 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
0.00%-45.45%-73.33%+1,100.00%-99.50%
Evogene Ltd. stock logo
EVGN
Evogene
-1.18%-9.64%+4.42%-24.07%-58.55%
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
-14.00%+10.26%+7.50%-29.51%-86.13%
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
0.00%0.00%0.00%0.00%-78.80%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
1.00
SellN/AN/A
Evogene Ltd. stock logo
EVGN
Evogene
1.00
SellN/AN/A
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
0.00
N/AN/AN/A
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest CARM, EVGN, PTPI, and VINC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/8/2026
Evogene Ltd. stock logo
EVGN
Evogene
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 8/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
$10.77M0.00N/AN/A($0.67) per share0.00
Evogene Ltd. stock logo
EVGN
Evogene
$3.85M1.25N/AN/A$0.66 per share0.83
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
$5.11M0.03N/AN/A$4.04 per share0.00
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
N/AN/AN/AN/A$10.50 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
-$60.48M$0.730.00N/AN/A-254.28%N/A-192.17%11/5/2026 (Estimated)
Evogene Ltd. stock logo
EVGN
Evogene
-$8.48M-$0.91N/AN/AN/A-694.18%-156.53%-86.80%N/A
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
-$8.16M-$0.36N/AN/AN/AN/A-78.22%-23.50%N/A
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
-$40.16M-$5.31N/AN/AN/AN/A-248.33%-132.73%8/27/2026 (Estimated)
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
N/AN/AN/AN/AN/A
Evogene Ltd. stock logo
EVGN
Evogene
N/AN/AN/AN/AN/A
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
N/AN/AN/AN/AN/A
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
N/A
0.48
0.48
Evogene Ltd. stock logo
EVGN
Evogene
N/A
3.57
3.54
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
1.58
0.85
0.74
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
N/A
2.17
2.17

Institutional Ownership

CompanyInstitutional Ownership
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
44.27%
Evogene Ltd. stock logo
EVGN
Evogene
10.40%
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
12.34%
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
44.02%

Insider Ownership

CompanyInsider Ownership
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
6.90%
Evogene Ltd. stock logo
EVGN
Evogene
7.40%
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
12.25%
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
15.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
2041.85 million38.91 millionNo Data
Evogene Ltd. stock logo
EVGN
Evogene
1408.72 million8.07 millionNo Data
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
2031.16 million9.93 millionNot Optionable
Vincerx Pharma, Inc. stock logo
VINC
Vincerx Pharma
605.23 million1.89 millionNot Optionable

Recent News About These Companies

Antibody Drug Conjugates (ADC) Market Research and Competitive Landscape Report 2026 - Extensive Analysis of Over 180 Companies and More Than 290 Drugs
April 14, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/antibody-drug-conjugates-adc-market-095100337.html
Contrasting Vincerx Pharma (NASDAQ:VINC) and iBio (NYSE:IBIO)
January 18, 2026  |  defenseworld.netD
Vincerx Pharma, Inc. Announces Additional Adjournment of Special Meeting - Urges Stockholders ...
July 16, 2025  |  gurufocus.comhttps://www.gurufocus.com/news/2982429/vincerx-pharma-inc-announces-additional-adjournment-of-special-meeting--urges-stockholders-to-vote-for-approval-of-dissolution-proposal--vinc-stock-news
Vincerx Pharma, Inc. Announces Additional Adjournment of Special Meeting - Urges Stockholders to Vote FOR Approval of Dissolution Proposal
July 16, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/07/16/3116827/0/en/Vincerx-Pharma-Inc-Announces-Additional-Adjournment-of-Special-Meeting-Urges-Stockholders-to-Vote-FOR-Approval-of-Dissolution-Proposal.html
Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders | The ... - The Manila Times
July 9, 2025  |  manilatimes.netM
Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders - Morningstar
July 9, 2025  |  morningstar.comM
Vincerx Pharma, Inc. Common Stock (VINC) - Yahoo Finance
July 8, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/quote/VINC/financials/
Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders
July 7, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/07/07/3111291/0/en/Vincerx-Pharma-Inc-Urges-Stockholders-to-Vote-FOR-Approval-of-Dissolution-Proposal-and-Announces-Potential-Range-for-Distributions-to-Stockholders.html
Vincerx Pharma, Inc. (VINC) - Yahoo Finance
July 2, 2025  |  ca.finance.yahoo.comhttps://ca.finance.yahoo.com/quote/VINC/press-releases/
Vincerx Pharma, Inc. Announces Adjournment of Special Meeting - Will Reconvene Meeting on July 16, 2025 to Secure Votes Needed to Approve Dissolution Proposal
June 18, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/06/18/3101905/0/en/Vincerx-Pharma-Inc-Announces-Adjournment-of-Special-Meeting-Will-Reconvene-Meeting-on-July-16-2025-to-Secure-Votes-Needed-to-Approve-Dissolution-Proposal.html
Vincerx Pharma announces plan to delist from Nasdaq
April 18, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/vincerx-pharma-announces-plan-to-delist-from-nasdaq-1034597516
Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC
April 17, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/vincerx-pharma-inc-announces-intent-204500865.html
Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC
April 17, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/04/17/3063864/0/en/vincerx-pharma-inc-announces-intent-to-delist-from-nasdaq-and-deregister-with-the-sec.html
Vincerx's final merger attempt collapses, leaving ADC biotech to wind down
April 9, 2025  |  fiercebiotech.comF
Vincerx terminates letter of intent with Global Digital, initiates wind down
April 9, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/vincerx-terminates-letter-of-intent-with-global-digital-initiates-wind-down-1034562524
Financially struggling drugmaker's potential rescue falls apart. It now will wind down
April 9, 2025  |  bizjournals.comhttps://www.bizjournals.com/sanfrancisco/news/2025/04/08/cancer-vincerx-pharma-qumulusai-merger-fails.html
Vincerx Pharma Announces Termination of Letter of Intent and Board Authorization to Pursue Wind-Down Activities
April 8, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/04/08/3057992/0/en/Vincerx-Pharma-Announces-Termination-of-Letter-of-Intent-and-Board-Authorization-to-Pursue-Wind-Down-Activities.html
Vincerx Pharma announces non-binding LOI for Qumulus AI combination
March 18, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/vincerx-pharma-announces-non-binding-loi-for-qumulus-ai-combination-1034489795
Vincerx Pharma, Inc.: Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI
March 18, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-03/64858522-vincerx-pharma-inc-vincerx-pharma-announces-non-binding-letter-of-intent-for-business-combination-with-qumulusai-399.htm
Vincerx, left in limbo by collapsed deal, moves to merge with AI company to escape cash crisis
March 18, 2025  |  fiercebiotech.comF

New MarketBeat Followers Over Time

Media Sentiment Over Time

Carisma Therapeutics stock logo

Carisma Therapeutics NASDAQ:CARM

$0.0012 0.00 (0.00%)
As of 08/26/2026 12:29 PM Eastern

Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Evogene stock logo

Evogene NASDAQ:EVGN

$0.55 +0.01 (+1.47%)
As of 10:10 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

Petros Pharmaceuticals stock logo

Petros Pharmaceuticals NASDAQ:PTPI

$0.0044 0.00 (-12.00%)
As of 09:53 AM Eastern

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.

Vincerx Pharma stock logo

Vincerx Pharma NASDAQ:VINC

$0.01 0.00 (0.00%)
As of 08/26/2026 12:22 PM Eastern

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas